Video

Don’t trust interface dermatitis to diagnose dermatomyositis


 

REPORTING FROM ICCLE 2018

Dermatologists and rheumatologists are mistaken if they think interface dermatitis is the sine qua non biopsy finding of dermatomyositis (DM), according to David Fiorentino, MD, PhD, professor of dermatology, rheumatology, and immunology at Stanford (Calif.) University.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Interface dermatitis on skin biopsy is “felt to be almost required by many people to make the diagnosis,” but he and his associates found that it was not present in about a quarter of a cohort of patients with DM. “We don’t want a clinician” to rule out the diagnosis based on its absence on a biopsy, “when its actually quite possible that the patient could have disease,” Dr. Fiorentino said at the International Conference on Cutaneous Lupus Erythematosus.

In general, skin biopsies in DM are tricky. “All of us take them, but we don’t really know how to interpret the information that comes back ... because we don’t really know how often many of [the associated] findings are seen” in DM patients, he noted.

One of the main concerns is to rule out lupus, but interface dermatitis is found in many of its cutaneous forms, as well as in graft-versus-host disease and other diseases.

So what’s a clinician to do? Fortunately, direct immunofluorescence can help. A positive lupus band test helps rule out DM, and the membrane attack complex helps rule it in, both with a good degree of certainty. In a video interview, Dr. Fiorentino explained these tests and how to use them.

Dr. Fiorentino had no relevant disclosures.

aotto@mdedge.com

Recommended Reading

ANA assay results differ widely in established lupus patients
MDedge Rheumatology
VIDEO: PPACMAN aims to advance the combined rheum-derm clinic approach in the community
MDedge Rheumatology
VIDEO: Considering systemic disease in dermatology patients
MDedge Rheumatology
VIDEO: Cannabinoids in dermatology
MDedge Rheumatology
Bloating. Flatulence. Think SIBO
MDedge Rheumatology
Bacteria seen as potential lupus triggers
MDedge Rheumatology
Dermatology practice gaps: improving medication management
MDedge Rheumatology
VIDEO: Skin exam crucial in rheumatic diseases, expert says
MDedge Rheumatology
New agents may bring hope for SLE patients
MDedge Rheumatology
Caution crucial for stem cell transplant in scleroderma, despite potential interest
MDedge Rheumatology